Discussion  by unknown
literature, we find that the current rate of embolization is the
same as was found in a 2004 survey of AGA proctors,5
whereas the PER rate is 3 times that reported in 2004 by
AGA investigators.4 Embolized devices often require oper-
ative intervention, and there is a risk of damage to cardiac
structures with catheter removal. Comparison of throm-
boembolitic event rates with other publications reveals that
it may be a bigger problem than is currently believed.
Only 1 such complication was found in 3 major studies
(including 2 specifically aimed at detecting thrombosis
rates),9-11 and a report in 2006 claims to be first to report
stroke from an Amplatzer device.12
Comparison with other publications also confirms a lower
published rate of death and serious complications than or find-
ings indicate.13-16 From 2003 to 2006, 5 case reports of device
erosion and perforation are found in the literature, and these
seem to be accounted for in theMAUDE database.17-21 Twice
before, investigators have published results of the reported
PER events from the MAUDE database,3,22 and there con-
tinues to be debate over the cause of this complication. The
findings of Divekar and colleagues22 highlight that larger de-
vices (>25 mm) do not seem to be overrepresented in the
known events and that many patients with oversized devices
do not experience perforation. We conclude that this seems to
be a more frequently encountered complication with a high
mortality but make no conclusions about cause.
CONCLUSIONS
The overall mortality for device and surgical closure of
the atrial septum seems equivalent, and the need for subse-
quent operation (surgical rescue) may be more common in
patients undergoing device closure than reoperation is in
patients undergoing surgical closure. Complications from
device closure tend to be serious and most often require
urgent or emergency operative management, whereas the
mortality for surgical management of a device complication
appears higher than that of elective ASD closure. Further
information is required in the form of postmarketing surveil-
lance, such as a mandatory user registry with periodic end-
user notification.
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Dr Carl L. Backer (Chicago, Ill). I want to congratulate Dr Di-
Bardino and colleagues at Children’s Hospital Boston for their very
clever idea of mining the MAUDE database to determine the inci-
dence of adverse events involving the Amplatzer septal occluder
device. I first became aware of this database at the AATS in Tor-
onto in 2004 when Richard Jonas debated Andrew Reddington
about this very topic. A brief look at that MAUDE database is quite
an eye-opener.
This is a very timely presentation and an important analysis. The
issue of device closure was the first paper at the STS in the Plenary
Session this year. In that paper, Dr Tara Karamlou also mined a da-
tabase, the Nationwide Inpatient Sample and ICD-9 procedure and
diagnosis codes. She discovered an increased incidence of ASD
closure mostly due to a sudden and dramatic rise in percutaneous
closure beginning in the year 2001.
The comparison of the MAUDE database to the STS database
clearly demonstrates the importance of our own congenitalrdiovascular Surgery c Volume 137, Number 6 1339
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Ddatabase. When I debated this topic at the ACC 3 years ago, the car-
diologists complained that there is no MAUDE database for sur-
geons. The STS database is our answer to that issue.
I have three questions for you, and they relate to your numerator
and your denominator.
My first question relates to the numerator in your analysis. There
were 223 adverse events and 17 deaths related to the Amplatzer de-
vice. At the AATS meeting in 2006, when we had a similar discus-
sion, I asked this audience how many people had taken Amplatzer
devices out of various parts of the body; nearly everyone in the
room raised their hand. Is it possible that the MAUDE database
might only be capturing the tip of the iceberg, and how confident
are you in your numerator?
Dr DiBardino. Thank you Dr Backer. That’s a tricky question
to answer. I presented this data to the interventional cardiologists
in Boston before I left and it’s their sense that this is the tip of
the iceberg. There are folks who place these devices who don’t
know about the MAUDE database. And that makes me very suspi-
cious that our numerator is, in fact, grossly under-reported.
There was an interesting study published by the United States
General Accounting Office that stated that 0.5% of all device-re-
lated complications ever make it to the FDA—0.5%. And that
also makes me very wary of this numerator. I think that this is
the tip of the iceberg.
Dr Backer. My second question relates to the denominator. The
analysis of the predicted complication rate of the Amplatzer device
hinges on this number. You noted in your manuscript that a request
of AGA Medical was made for an estimate of implants over the
time of the study period and that this request was denied. You de-
rived an estimate of 18,333 implants, although the paper you
quoted was from 2004. This makes the calculated mortality of
the Amplatzer device 1 in 1,000. How comfortable are you with
the denominator that you have given us?
Dr DiBardino. Well, the 2 papers that I mentioned (from 2004
and 2007) were both papers that used implants estimates based on
AGA medical data and the 2004 paper was published by folks fi-
nancially tied to AGA medical. So the number 18,333 comes
from an estimation that was made of implants over about a 2-
and-a-half year period; we simply converted that estimate into
‘‘number of implants per month’’ and multiplied it by 66 months,
or 5.5 years. I think it’s the best we can do. I can’t speak to its ac-
curacy because I cannot externally validate it, but I do submit that it
is an honest effort and the best we can do.
Dr Backer.Andwhat about the company not responding to your
requests?
Dr DiBardino.Well, yes, it was actually interesting. I called the
Boston AGAMedical representative (who services Children’s Hos-
pital Boston) and asked for the actual implant numbers. They
looked into it, and I received an electronic mail correspondence
subsequently that said that that information would not be available
for me. I just can’t get it.
Dr Backer. All right. My final question relates to the incidence
of complications in the MAUDE database over time. It was a little
disturbing to see that slide that showed that actually the number of
reports are increasing per year. This could possibly be related to an
increase in the total number of devices implanted or that there is not
a positive learning curve that we would hope would happen. When
we discussed this in 2006, Dr del Nido noted that the interventional1340 The Journal of Thoracic and Cardiovascular Sucardiologists are now looking at things like the size of the aortic
rim, not oversizing the device, more careful follow-up, and that
this would, indeed, actually reduce the incidence of these compli-
cations. What’s your feeling, looking at this database, whether
the incidence of these complications is going up or down over time?
Dr DiBardino. Well, the histogram that I showed is not very
useful because it, of course, does not answer the question about
whether the increase in reported events is simply that people are re-
porting them more often or are they being implanted more often
such that the frequency of complications cannot be ascertained.
The cardiology literature does comment on the fact that, after the
device was first approved for general use, there was perceived to
be a rise in the complication rate and this has been ascribed to
the unfamiliarity of new cardiologists to that device. Beyond
around 2004–2005, we sort of lose track of that in the literature. I
really don’t have enough information to truly accurately know
what the trend is in complication rate.
Dr Jeffrey P. Jacobs (St. Petersburg, Fla). First, I would like to
congratulate you for doing a great job and making an outstanding
presentation. It really makes me proud to see our database, the
STS Congenital Heart Surgery Database, mature to the point that
it can be used for a study like this one. I think you did a great job
with this study and presented it quite well.
I think one could criticize the data from the STS database by say-
ing that it stops at hospital discharge, and we do not knowwhat hap-
pens after hospital discharge. This criticism underscores the
importance of what we are trying to accomplish in the STS database
by incorporating HIPAA Compliant Unique Patient, Surgeon, and
Hospital Identifier Fields into the STS Database, and creating
a framework where our database can be used as a tool for longitu-
dinal follow-up. The STS Adult Cardiac Database has incorporated
these identifier fields as of January 1, 2008. These fields will be in-
corporated into the STS Thoracic Database on January 1, 2009, and
into the STS Congenital Heart Surgery Database on January 1,
2010. I think that this accomplishment is going to mature our
STS database.
My question is: How would you recommend maturing the way
that we follow these devices, and the device databases, based on
what you have learned from this study?
Dr DiBardino. Thank you, Dr Jacobs. In my time as a junior
resident in general surgery in Dr Chuck Fraser’s research lab, I be-
came interested in databases and outcomes analysis and hope to
make that the backbone of my own academic career as I progress.
I think the answer to your question is that if you look at the his-
tory of the FDA in cardiovascular surgery, there are numerous ex-
amples (the Bjork-Shiley prosthesis, the Silzone coating that was
transiently used on St. Jude valves) of where postmarketing surveil-
lance has become important. Even changed the way products are
handled, what their recommendations are for their placement and,
in some cases, products being eliminated from the market. I think
what we’re not going to have is a head-to-head trial. It’s just not go-
ing to happen. I think an easy solution would be simply creating
a registry, an implant registry, with periodic end-user notification.
That has been done with LVADs; it is easy and effective and it
would give us real answers about what the numerators and denom-
inators are.
Dr Shunji Sano (Okayama City, Japan). Just over one year, we
studied theAmplatzerASDclosure. In the last year, our cardiologistsrgery c June 2009
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sure on 10 patients. And we have no host mortality and no surgical
rescue, one temporary episode of thromboembolism. So the result
is completely different from yours. I think maybe the difference is
the indication. If you have wide range of indications, you have
more complications.
The question is: Do you have surgeons involved in the indication
of Amplatzer ASD closure and surgical closure? Because we, in our
unit, the surgeon is completely involved in the indication of the
technique, 2 techniques, and our young surgical fellow is also in-
volved in this procedure.
Dr DiBardino. Well, I think what you’re describing is very
common when you examine the results from a single center that
has excellent physicians who are doing procedures that they are
very experienced with. And if you look at single-center reporting
from the United States, you’ll find the results that you’ve just de-
scribed: No mortality, no erosions, no embolizations. But whenThe Journal of Thoracic and Cyou apply a product to the general audience and you allow people
who are less familiar with it, then, to start using it, there is going to
be a learning curve. And I think that’s part of what we’re seeing in
this analysis.
In Boston, the surgeons are not involved in the decision, by and
large, to place implants or devices. One thing I will say, however, is
that our interventionalists (one of whom is my coauthor on this
paper) are gifted and talented but also careful. What I mean to say
is that they are very careful about their selection and techniques in
terms of using stop-flow technique for balloon sizing, paying careful
attention to the amount of retro-aortic rim, and being very careful not
to oversize devices. They’re probably more careful about it than
they are at some other places and there not afraid to send certain
patients to the operating room. All of this leads, as it has at your cen-
ter, to a low complication rate. But I think that it’s difficult to extrap-
olate those results to everywhere, all over, because of the different
comfort level and skill level of the physicians who provide care.ardiovascular Surgery c Volume 137, Number 6 1341
